CoChat

Risk factors and clinical outcomes of breakthrough yeast bloodstream infections in patients with hematological malignancies in the era of newer antifungal agents

Open access

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

Although yeast bloodstream infections (BSIs) are increasingly being reported in patients with hematological malignancies undergoing antifungal therapy, clinical information regarding breakthrough infections is scarce. The aim of this study was to determine the risk factors for and clinical outcomes of breakthrough yeast BSIs in patients with hematological malignancies in the era of newer antifungal agents. Between 2011 and 2014, all consecutive patients with hematological malignancies who developed yeast BSIs were included in a case-control study wherein breakthrough infections (cases) and de novo infections (controls) were compared. Of 49 patients with yeast BSIs, 21 (43%) met the criteria for breakthrough infections. The proportions of Candida krusei and Candida tropicalis in the cases and controls were significantly different (32% [7/22] vs. 3% [1/29], P = .015; 5% [1/22] vs. 38% [11/29], P = .007, respectively). Acute leukemia, presence of a central venous catheter and neutropenia in the 3 days prior to BSI were significant risk factors for breakthrough infections. Six-week mortality rates was 33% [7/21] in the cases and 43% [12/28] in the controls (P = .564). Refractory neutropenia and the Pitt bacteremia score were independent predictors of 6-week mortality. In conclusion, breakthrough infections accounted for a significant proportion of yeast BSIs in patients with hematological malignancies. However, these infections did not increase the risk of death by themselves. Our results suggest that current clinical management of breakthrough yeast BSIs, which includes switching to a different antifungal class and prompt catheter removal is reasonable.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/mmy/myx038

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Annual use of antifungal drugs at the Catholic Blood and Marrow Transplantation Center from January 2011 to December 2014. DDD, defined daily doses. Note. Posaconazole was only available through the Korean Orphan Drug Center by early 2014 in Korea, and no statistics could be calculated.
Figure 1. Annual use of antifungal drugs at the Catholic Blood and Marrow Transplantation Center from January 2011 to December 2014. DDD, defined daily doses. Note. Posaconazole was only available through the Korean Orphan Drug Center by early 2014 in Korea, and no statistics could be calculated.CC BY-NC · PubMed Central
Figure 2. Distribution of yeast species causing bloodstream infections (BSIs) in patients with hematological malignancies. Note. Data are no. (%) of isolates. aCandida dubliniensis (n = 1), Candida guilliermondii (n = 1), Candida inconspicua (n = 1), and Candida pelliculosa (n = 1) in breakthrough BSIs; Candida famata (n = 1), and Candida lusitaniae (n = 2) in de novo BSIs. bSaccharomyces cerevisiae (n = 1), Trichosporon asahii (n = 1), and Pseudozyma aphidis (n = 1) in breakthrough BSIs; Saccharomyces cerevisiae (n = 1) in de novo BSI.
Figure 2. Distribution of yeast species causing bloodstream infections (BSIs) in patients with hematological malignancies. Note. Data are no. (%) of isolates. aCandida dubliniensis (n = 1), Candida guilliermondii (n = 1), Candida inconspicua (n = 1), and Candida pelliculosa (n = 1) in breakthrough BSIs; Candida famata (n = 1), and Candida lusitaniae (n = 2) in de novo BSIs. bSaccharomyces cerevisiae (n = 1), Trichosporon asahii (n = 1), and Pseudozyma aphidis (n = 1) in breakthrough BSIs; Saccharomyces cerevisiae (n = 1) in de novo BSI.CC BY-NC · PubMed Central
Figure 3. Comparison of the distribution of yeast species isolated from breakthrough and de novo yeast bloodstream infections.
Figure 3. Comparison of the distribution of yeast species isolated from breakthrough and de novo yeast bloodstream infections.CC BY-NC · PubMed Central
Figure 4. Kaplan–Meier estimates of survival in patients with breakthrough and de novo yeast bloodstream infections.
Figure 4. Kaplan–Meier estimates of survival in patients with breakthrough and de novo yeast bloodstream infections.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 24

Metadata

Authors
Kim, S.-H., Choi, J.-K., Cho, S.-Y., Lee, H.-J., Park, S. H., Choi, S.-M., Lee, D.-G., Choi, J.-H., Yoo, J.-H., & Lee, J.-W.
Affiliations
  • The Catholic University of Korea Incheon St. Mary's Hospital (KR)
  • Catholic University of Korea (KR)
Corresponding author
Lee, Dong-Gun
Venue
Medical Mycology
Published
2017-05-19
Volume
56
Issue
2
Pages
197-206
ISSN
  • 0268-1218 (ISSN-L)
  • 1369-3786
  • 1460-2709
OpenAlex
W2616781930
Cited by
24
References
31
Citations by year
2026: 2 · 2024: 3 · 2023: 3 · 2022: 5 · 2021: 3 · 2020: 4 · 2019: 2 · 2018: 2
FWCI
1.68
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Medical Mycology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
  • Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
Keywords
breakthrough infection, hematologic malignancies, antifungal therapy, Candida krusei, Candida tropicalis, acute leukemia, central venous catheters, neutropenia, mortality, risk factors, Pitt bacteremia score, catheter removal
MeSH terms
Aged, Antifungal Agents, Female, Fungi, Humans, Male, Middle Aged, Risk Factors, Case-Control Studies, Fungemia, Treatment Outcome, Hematologic Neoplasms, Tertiary Care Centers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risk factors and clinical outcomes of breakthrough yeast bloodstream infections in patients with hematological malignancies in the era of newer antifungal agents. https://app.cochat.ai/papers/10.1093/mmy/myx038
The paper
Kim, S.-H., Choi, J.-K., Cho, S.-Y., Lee, H.-J., Park, S. H., Choi, S.-M., Lee, D.-G., Choi, J.-H., Yoo, J.-H., & Lee, J.-W. (2018). Risk factors and clinical outcomes of breakthrough yeast bloodstream infections in patients with hematological malignancies in the era of newer antifungal agents. Medical Mycology. https://doi.org/10.1093/mmy/myx038

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.